VTRS Viatris Inc. - Common Stock
NASDAQ · Pharmaceuticals · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 6, 2026
$17,60
· % zakresu 52 tyg.
· powyżej minimum
· do maksimum
$9,6952tyg. minimum
$18,4352tyg. maksimum
P/E
-4.2
EPS
$-3.00
Przychody
$14.30B
Twoje odznaki
Zakres 52 tyg.
$10–$18
Ocena Analityków
BUY
Cena Docelowa
$19
P/E
-4.2
ROE
-23.2%
Marża Zysku Netto
-24.6%
Twój pasek odznak jest pusty — przypnij metrykę w dowolnym miejscu na tej stronie.
VTRS Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$17.60
P/E
-4.2
EPS
$-3.00
Przychody
$14.30B
ROE
-23.2%
D/E Dług/Kapitał (MRQ)
0.9
Zakres 52 tyg.
$10–$18
VTRS Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
zakres
kreski
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
Podziały akcji
| Data ex-dywidendy | Podział | Typ |
|---|---|---|
| 9 października 2003 | 3-for-2 | Naprzód |
| 28 stycznia 2003 | 3-for-2 | Naprzód |
| 16 sierpnia 1995 | 3-for-2 | Naprzód |
| 3 sierpnia 1992 | 2-for-1 | Naprzód |
O Viatris Inc. - Common Stock Przegląd firmy z Wikipedii
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community.
Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue. In 2026, Viatris ranked 100 on Time Magazine's World's Most Impactful Companies.
History
On November 16, 2020, Upjohn merged with Mylan in a Reverse Morris Trust transaction and changed its name to Viatris. At that time, Michael Goettler became chief executive officer. Following the combination, the company began trading on the NASDAQ using the ticker symbol VTRS. In December 2020, the company announced a cost-reducing restructuring plan that would impact up to 20% of its global workforce, or 9,000 jobs at its facilities around the world.
In 2021, Viatris was ranked 5th by Fortune on its annual "Change the World" list for having "transformed the treatment of HIV around the world in the [previous] five years through the first low-cost antiretroviral drug for first-line treatment of HIV and a children's version in the form of fruit-flavored tablets that dissolve in liquid. In February 2022, Viatris announced an agreement where it will contribute to Biocon Biologics its biosimilars portfolio and related commercial and operational capabilities in exchange for up to $3.335 billion, including a stake of at least 12.9% in Biocon Biologics. The transaction was completed in November 2022. In November 2022, the business agreed to acquire Oyster Point Pharma and Famy Life Sciences for an aggregate of $700–750 million to create an ophthalmology division. The acquisitions closed in January 2023.
From 2021 to 2025, Viatris was recognized by Forbes as one of the world's best employers and in 2021 by Newsweek as one of America's most responsible companies. On April 1, 2023, Scott A. Smith became Viatris' CEO, succeeding Michael Goettler. Smith previously served on the company's board since 2022. In April 2023, Viatris was recognized by LinkedIn as one of the 25 best companies to work for in India, and one of the 25 best companies offering career development in Ireland.In May 2023 and 2024, USA Today included Viatris in its list of 450 US companies that have reduced their greenhouse gas emissions intensity from 2019 to 2021. In June 2023, Viatris was named to the Forbes Global 2000 list of the world's largest companies. In October 2023, Viatris reached agreements to divest from almost all of its OTC business, its women’s healthcare business, and its India-based active pharmaceutical ingredients business for a total of about $3.6 billion.
In late December 2024, Viatris disclosed that the U.S. FDA had issued a warning letter and an import alert concerning the company's drug-making facility in Indore, India. The import alert affects 11 actively distributed products, which will no longer be accepted into the U.S. until the warning letter is lifted, while four products were conditionally exempted due to shortages. The violations cited by the FDA included subpar quality control and improper management of manufacturing defect. In response, the company announced that it has taken corrective and preventative actions.
Predecessors
The following is an illustration of the company's major mergers and acquisitions and historical predecessors:
Products
The company produces and sells a variety of medicines, with 1,400 approved therapeutic molecules in its portfolio. It owns brands (like Viagra, Xanax, Lipitor), generics, including branded and complex generics, biosimilars, and over-the-counter (OTC) drugs and active pharmaceutical ingredients. Viatris products cover therapeutic areas including cardiovascular, infectious disease, oncology, immunology, CNS and anesthesia, women's healthcare, diabetes and metabolism, gastroenterology, respiratory and allergy, and dermatology.
The following products have been newly launched or received regulatory approvals since Viatris was established include:
Dolutegravir: In December 2020, received FDA approval to treat children with HIV/AIDS in low to middle income countries. The formulation is strawberry-flavored to make it easier to give to children and was made available at a 75% discount compared to previous treatments.
Breyna (budesonide and formoterol fumarate dihydrate inhalation aerosol): In March 2022, received approval from the US FDA in March 2022 as the first generic version of Symbicort for the treatment of asthma and COPD.
GA Depot (long-acting version of glatiramer acetate): In August 2023, received New Drug Application acceptance from the US FDA as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis.
Abacavir/dolutegravir/lamivudine: In September 2023, received tentative US FDA approval for a New Drug Application through the President's Emergency Plan for AIDS Relief (PEPFAR) for the treatment of HIV-1 infection in pediatric patients.
Ryzumvi (phentolamine ophthalmic solution 0.75%): In September 2023, received FDA approval for the treatment of mydriasis caused by adrenergic agonist or parasympatholytic agents or a combination of those drugs. It was previously known as Nyxol.
Partnerships
Following the formation of Viatris, the company became a member of the Biosimilars Forum, a trade organization that advocates for greater biosimilar usage. Viatris partnered with the American College of Cardiology, the NCD Alliance, and the World Heart Federation to create the NCD Academy, a platform to help fight non-communicable diseases around the world.
In December 2020, the company worked with Sesame Workshop to create resources to help children and their caregivers manage their social and emotional needs impacted by the COVID-19 pandemic. In April 2021, the company partnered with Atomo Diagnostics and Unitaid to expand access to HIV self-testing to 135 countries and lower the price of the tests by around 50%.
In February 2024, Viatris entered into an agreement with Idorsia to collaborate on global research and development and the commercialization rights to Phase 3 pharmaceuticals selatogrel, a cardiac medication, and cenerimod, a novel immunology medication used to treat systemic lupus erythematosus. The agreement includes the potential to add more assets in the future.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
sektorHealthcare
branżaPharmaceuticals
pracownicy30 000
krajUS
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody$14.30B2018-12-31 → 2025-12-31
EPS$-3.002018-12-31 → 2025-12-31
Wolny przepływ pieniężny$1.94B2025-12-31 → 2025-12-31
Marża netto-24.6%2025-12-31 → 2025-12-31
Wycena i wskaźniki
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | VTRS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E | -4.2średnia z 5 lat ≈36.5 | ≈36.5 | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | VTRS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża brutto (TTM) | 34.8% | · | · | · | |
| Marża Operacyjna (TTM) | -0.59% | · | 8.2% | Słaby | |
| Marża EBITDA (TTM) | 18.4% | · | 5.2% | Słaby | |
| Marża przed opodatkowaniem (TTM) | -4.5% | · | 8.1% | Słaby | |
| Net Profit Margin (Marża Zysku Netto) | -24.6% | · | 3.3% | Słaby | |
| ROA | -8.9% | · | 5.9% | Słaby | |
| ROE | -23.2% | · | 12.2% | Słaby | |
| ROIC | -8.8% | · | -0.21% | Słaby |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | VTRS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | 0.9 | · | 1.2 | Niski dług | |
| Wskaźnik bieżący (MRQ) | 1.6 | · | 1.6 | Zgodnie z | |
| Quick Ratio (Wskaźnik Szybkości) | 0.6 | · | 0.9 | Niska płynność | |
| Dług długoterminowy / Kapitał własny (MRQ) | 0.8 | · | 1.2 | Niski dług | |
| Interest Coverage (Pokrycie odsetek) | -5.7 | · | · | · |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | VTRS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | -3.0%średnia z 5 lat ≈5.6% | ≈5.6% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | -4.2%średnia z 5 lat ≈-0.52% | ≈-0.52% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 3.7% | · | · | · | |
| EPS YoY | -97.1% | · | · | · | |
| Net Income YoY (Zysk Netto R/R) | -97.4% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | VTRS | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 0.4 | · | 0.5 | Słaby | |
| Inventory Turnover (Rotacja zapasów) | 2.4 | · | 1.4 | Najwyższa półka | |
| Receivables Turnover (Rotacja należności) | 4.6 | · | 5.4 | Słaby | |
| Revenue / Employee (Przychody / pracownika) | ≈$476.7K | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Dywidendy Stopa dywidendy, wskaźnik wypłaty, historia dywidend, 5-letni CAGR
Zannualizowane wypłaty≈$0.48
| Data ex-dywidendy | Kwota | Waluta | Stopa zwrotu |
|---|---|---|---|
| Sie 21, 2026 | $0,12 | USD | ≈2.9% |
| Maj 22, 2026 | $0,12 | USD | ≈2.9% |
| Mar 9, 2026 | $0,12 | USD | ≈3.4% |
| Lis 24, 2025 | $0,12 | USD | ≈4.5% |
| Sie 22, 2025 | $0,12 | USD | ≈4.5% |
| Maj 23, 2025 | $0,12 | USD | ≈5.8% |
| Mar 10, 2025 | $0,12 | USD | ≈5.1% |
| Lis 22, 2024 | $0,12 | USD | ≈3.6% |
| Sie 23, 2024 | $0,12 | USD | ≈4.1% |
| Maj 23, 2024 | $0,12 | USD | ≈4.6% |
| Mar 8, 2024 | $0,12 | USD | ≈3.9% |
| Lis 22, 2023 | $0,12 | USD | ≈5.1% |
| Sie 23, 2023 | $0,12 | USD | ≈4.4% |
| Maj 23, 2023 | $0,12 | USD | ≈5.2% |
| Mar 8, 2023 | $0,12 | USD | ≈4.5% |
| Lis 22, 2022 | $0,12 | USD | ≈4.3% |
| Sie 23, 2022 | $0,12 | USD | ≈4.6% |
| Maj 23, 2022 | $0,12 | USD | ≈4.0% |
| Lut 23, 2022 | $0,12 | USD | ≈3.1% |
| Lis 22, 2021 | $0,11 | USD | ≈2.5% |
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
8.0%
Następny raport
Lis 04, 2026
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 6, 2026 | $0.69 | $0.61 | 12.6% |
| 31 marca 2026 | Maj 6, 2026 | $0.59 | $0.51 | 15.2% |
| 31 grudnia 2025 | $0.57 | $0.54 | 4.8% | |
| 30 września 2025 | $0.67 | $0.63 | 5.8% | |
| 30 czerwca 2025 | $0.62 | $0.57 | 9.4% | |
| 31 marca 2025 | $0.50 | $0.50 | 0.14% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.30B | $14.74B | $15.43B | $16.26B | $17.89B | $11.95B | $11.50B | $11.43B | |
| Cost of Revenue | $9.29B | $9.12B | $8.99B | $9.77B | $12.31B | $8.15B | $7.60B | $7.43B | |
| Gross Profit | $5.01B | $5.62B | $6.44B | $6.50B | $5.58B | $3.80B | $3.90B | $4.00B | |
| R&D Expense | · | · | · | · | $751M | $555M | $640M | $704M | |
| SG&A Expense | $3.79B | $4.10B | $4.07B | $4.18B | $4.53B | $3.34B | $2.56B | $2.44B | |
| Operating Expenses | $7.68B | $5.61B | $5.67B | $4.88B | $5.61B | $4.01B | $3.18B | $3.10B | |
| Operating Income | $-2.66B | $10M | $766M | $1.61B | $-34M | $-211M | $716M | $906M | |
| Interest Expense | $471M | $550M | $573M | $592M | $636M | $498M | $517M | $542M | |
| Other Non-op | $-531M | $-83M | $10M | $1.79B | $6M | $-13M | $-44M | $-65M | |
| Pretax Income | $-3.67B | $-623M | $203M | $2.81B | $-664M | $-721M | $154M | $298M | |
| Income Tax | $-150M | $11M | $148M | $735M | $605M | $-51M | $138M | $-54M | |
| Net Income | $-3.51B | $-634M | $55M | $2.08B | $-1.27B | $-670M | $17M | $352M | |
| EPS (Basic) | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 | $0.03 | $0.69 | |
| EPS (Diluted) | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 | $0.03 | $0.68 | |
| Shares (Basic) | · | · | 1,200,300,000 | 1,212,100,000 | 1,208,800,000 | 601,200,000 | 515,700,000 | 514,500,000 | |
| Shares (Diluted) | · | · | 1,206,900,000 | 1,217,400,000 | 1,208,800,000 | 601,200,000 | 516,500,000 | 516,500,000 | |
| EBITDA | $135M | · | · | · | · | · | · | · |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.32B | $735M | $992M | $1.26B | $701M | $844M | $476M | $388M | |
| Short-term Investments | · | · | · | · | · | $39M | $27M | · | |
| Receivables | $3.03B | $3.22B | $3.70B | $3.81B | $4.27B | $4.84B | $3.06B | · | |
| Inventory | $4.00B | $3.85B | $3.47B | $3.52B | $3.98B | $5.47B | $2.67B | · | |
| Prepaid Expense | $1.44B | $1.71B | $2.03B | $1.81B | $1.96B | $1.71B | $552M | · | |
| Other Current Assets | $136M | $387M | $271M | $328M | $1.47B | $1.24B | $286M | · | |
| Current Assets | $9.79B | $9.52B | $12.98B | $10.64B | $10.90B | $12.87B | $6.76B | · | |
| PP&E (Net) | $2.61B | $2.67B | $2.76B | $3.02B | $3.19B | $3.46B | $2.15B | · | |
| PP&E (Gross) | $5.13B | $4.87B | $4.77B | $5.08B | $5.59B | $5.72B | $4.12B | · | |
| Accum. Depreciation | $2.52B | $2.20B | $2.01B | $2.06B | $2.40B | $2.26B | $1.97B | · | |
| Goodwill | $6.75B | $9.13B | $9.87B | $10.43B | $12.11B | $12.35B | $9.59B | $9.75B | |
| Intangibles | $15.10B | $17.07B | $19.18B | $22.61B | $26.13B | $29.68B | $11.65B | · | |
| Other Non-current Assets | $1.87B | $2.36B | $2.21B | $2.40B | $1.17B | $1.05B | $405M | · | |
| Total Assets | $37.19B | $41.50B | $47.69B | $50.02B | $54.84B | $61.55B | $31.26B | · | |
| Short-term Debt | · | · | · | $0 | $1.49B | $1.10B | $0 | · | |
| Current Liabilities | $7.09B | $5.78B | $7.78B | $6.75B | $9.88B | $10.56B | $5.57B | · | |
| Capital Leases | $178M | $179M | $165M | $181M | $201M | $230M | $176M | · | |
| Deferred Tax | $892M | $1.11B | $1.74B | $2.43B | $2.81B | $3.12B | $1.63B | · | |
| Other Non-current Liabilities | $2.01B | $1.94B | $1.52B | $1.76B | $1.93B | $2.48B | $961M | · | |
| Total Liabilities | $22.48B | $22.87B | $27.22B | $28.95B | $34.35B | $38.60B | $19.37B | · | |
| Long-term Debt | $14.41B | $14.05B | $18.13B | $19.27B | $21.59B | $24.74B | $12.72B | · | |
| Total Debt | $14.41B | · | · | · | · | · | · | · | |
| Common Stock | $12M | $12M | $12M | $12M | $12M | $12M | $6M | · | |
| Paid-in Capital | $18.80B | $18.92B | $18.81B | $18.65B | $18.54B | $18.44B | $8.64B | · | |
| Retained Earnings | $-388M | $3.42B | $4.64B | $5.18B | $3.69B | $5.36B | $6.03B | · | |
| Treasury Stock | $1.01B | $504M | $252M | $0 | $0 | $0 | $1000M | · | |
| AOCI | $-2.71B | $-3.21B | $-2.75B | $-2.76B | $-1.74B | $-858M | $-1.80B | · | |
| Stockholders' Equity | $14.71B | $18.64B | $20.47B | $21.07B | $20.49B | $22.95B | $11.88B | $12.17B | |
| Liabilities + Equity | $37.19B | $41.50B | $47.69B | $50.02B | $54.84B | $61.55B | $31.26B | · | |
| Shares Outstanding | · | · | · | · | · | · | 100 | · |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| D&A | $2.80B | $2.89B | $2.74B | $3.03B | $4.51B | $2.22B | $2.02B | $2.11B | |
| Stock-based Comp | $178M | $146M | $181M | $116M | $111M | $79M | $57M | $-3M | |
| Deferred Tax | $-476M | $-768M | $-387M | $-26M | $676M | $-213M | $-193M | $-264M | |
| Amort. of Intangibles | $2.35B | $2.35B | $2.32B | $2.50B | $2.70B | $1.61B | $1.58B | $1.61B | |
| Restructuring | · | · | · | · | $50M | $50M | $105M | · | |
| Other Non-cash | $3.33B | · | · | · | · | · | · | · | |
| Operating Cash Flow | $2.32B | $2.30B | $2.90B | $3.00B | $3.02B | $1.23B | $1.80B | $2.34B | |
| CapEx | $379M | $326M | $377M | $406M | $457M | $243M | $213M | $252M | |
| Investing Cash Flow | $-428M | $1.80B | $-864M | $1.47B | $-118M | $-301M | $-525M | $-1.21B | |
| Debt Issued | $0 | $0 | $300.0K | $1.88B | $1.71B | $983M | $7M | $2.58B | |
| Net Debt Issued | $-100.0K | · | · | · | · | · | · | · | |
| Stock Issued | $3M | $2M | $3M | $3M | $0 | $0 | · | · | |
| Stock Repurchased | $500M | $250M | $250M | $0 | $0 | $0 | $0 | $432M | |
| Net Stock Activity | $-498M | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-1.29B | $-4.33B | $-2.30B | $-3.88B | $-3.01B | $-606M | $-1.17B | $-1.09B | |
| Net Change in Cash | $612M | $-258M | $-269M | $556M | $-144M | $359M | $102M | $19M | |
| Taxes Paid | $445M | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.94B | · | · | · | · | · | · | · | |
| Levered FCF | $1.49B | · | · | · | · | · | · | · |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.1% | · | · | · | · | · | · | · | |
| Operating Margin | -18.6% | · | · | · | · | · | · | · | |
| Net Margin | -24.6% | · | · | · | · | · | · | · | |
| Pretax Margin | -25.6% | · | · | · | · | · | · | · | |
| EBITDA Margin | 0.95% | · | · | · | · | · | · | · | |
| ROA | -8.9% | · | · | · | · | · | · | · | |
| ROE | -23.2% | · | · | · | · | · | · | · | |
| ROIC | -8.8% | · | · | · | · | · | · | · |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.4 | · | · | · | · | · | · | · | |
| Quick Ratio | 0.6 | · | · | · | · | · | · | · | |
| Debt / Equity | 1.0 | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.8 | · | · | · | · | · | · | · | |
| Interest Coverage | -5.7 | · | · | · | · | · | · | · |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | · | · | · | · | · | · | · | |
| Inventory Turnover | 2.4 | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.6 | · | · | · | · | · | · | · |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | · | · | · | · | · | $0.00 | · | |
| Dividend Paid / Share | $0.48 | $0.48 | $0.48 | $0.48 | $0.33 | · | · | · | |
| EPS (TTM) | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 | $0.03 | · |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -3.0% | -4.5% | -5.1% | -9.1% | 49.7% | · | · | · | |
| Revenue CAGR 3Y | -4.2% | -6.2% | 8.9% | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.7% | · | · | · | · | · | · | · | |
| EPS YoY | · | · | -97.1% | · | · | · | · | · | |
| Net Income YoY | · | · | -97.4% | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14.30B | $14.74B | $15.43B | $16.26B | $17.89B | $11.95B | $11.50B | · | |
| Net Income TTM | $-3.51B | $-634M | $55M | $2.08B | $-1.27B | $-670M | $17M | · | |
| Market Cap | · | · | · | · | · | · | $2.0K | · | |
| P/E | -4.2 | -23.5 | 216.6 | 6.5 | -12.9 | -16.9 | 670.0 | · | |
| P/S | · | · | · | · | · | · | 0.0 | · | |
| Earnings Yield | -24.1% | -4.3% | 0.46% | 15.4% | -7.8% | -5.9% | 0.15% | · |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.76B | $3.52B | $3.70B | $3.76B | $3.58B | $3.25B | $3.53B | $3.75B | $3.80B | $3.66B | $3.84B | $3.94B | $3.92B | $3.73B | $3.88B | $4.08B | |
| Cost of Revenue | $2.30B | $2.36B | $2.56B | $2.39B | $2.25B | $2.09B | $2.31B | $2.29B | $2.35B | $2.16B | $2.24B | $2.25B | $2.31B | $2.19B | $2.60B | $2.33B | |
| Gross Profit | $1.46B | $1.16B | $1.15B | $1.37B | $1.33B | $1.16B | $1.22B | $1.46B | $1.45B | $1.50B | $1.60B | $1.69B | $1.61B | $1.54B | $1.27B | $1.75B | |
| R&D Expense | $248M | $249M | · | $250M | $219M | $222M | · | $198M | $204M | $200M | · | $211M | $208M | $183M | · | $175M | |
| SG&A Expense | $1.13B | $929M | $1.03B | $887M | $929M | $948M | $1.05B | $1.00B | $1.04B | $1.02B | $1.03B | $1.05B | $1.03B | $959M | $1.27B | $1.02B | |
| Operating Expenses | $1.45B | $1.24B | $1.34B | $1.19B | $1.10B | $4.04B | $1.39B | $1.23B | $1.69B | $1.30B | $2.05B | $1.24B | $1.24B | $1.14B | $1.48B | $1.19B | |
| Operating Income | $6M | $-80M | $-193M | $179M | $233M | $-2.88B | $-180M | $226M | $-240M | $204M | $-454M | $452M | $369M | $400M | $-201M | $560M | |
| Interest Expense | $121M | $120M | $120M | $120M | $117M | $116M | $120M | $146M | $146M | $138M | $141M | $142M | $144M | $147M | $147M | $153M | |
| Other Non-op | $50M | $-48M | $-31M | $-67M | $-334M | $-99M | $-226M | $10M | $-6M | $139M | $-260M | $92M | $108M | $70M | $1.82B | $21M | |
| Pretax Income | $-64M | $-247M | $-343M | $-8M | $-217M | $-3.10B | $-526M | $90M | $-392M | $205M | $-855M | $402M | $333M | $323M | $1.47B | $428M | |
| Income Tax | $55M | $-424M | $-3M | $120M | $-212M | $-55M | $-10M | $-4M | $-65M | $91M | $-89M | $71M | $69M | $98M | $458M | $73M | |
| EPS (Basic) | $-0.10 | $0.15 | $-0.34 | $-0.11 | $0.00 | $-2.55 | $-0.44 | $0.08 | $-0.27 | $0.10 | $-0.64 | $0.28 | $0.22 | $0.19 | $0.83 | $0.29 | |
| EPS (Diluted) | $-0.10 | $0.15 | $-0.34 | $-0.11 | $0.00 | $-2.55 | $-0.43 | $0.08 | $-0.27 | $0.09 | $-0.63 | $0.27 | $0.22 | $0.19 | $0.83 | $0.29 | |
| Shares (Basic) | 1,163,300,000 | 1,155,400,000 | · | 1,164,600,000 | 1,173,000,000 | 1,192,400,000 | · | 1,193,500,000 | 1,191,100,000 | 1,195,200,000 | · | 1,199,500,000 | 1,199,000,000 | 1,202,500,000 | · | 1,212,500,000 | |
| Shares (Diluted) | 1,163,300,000 | 1,175,300,000 | · | 1,164,600,000 | 1,173,000,000 | 1,192,400,000 | · | 1,200,400,000 | 1,191,100,000 | 1,209,500,000 | · | 1,207,600,000 | 1,203,500,000 | 1,205,600,000 | · | 1,218,100,000 | |
| EBITDA | $6M | $596M | · | $179M | $233M | $-2.22B | · | $226M | $-240M | $895M | · | $452M | $369M | $1.13B | · | $560M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $886M | $1.80B | $1.32B | $975M | $566M | $755M | $735M | $1.88B | $917M | $1.01B | $992M | $1.31B | $629M | $507M | $1.26B | $647M | |
| Receivables | $3.13B | $3.08B | $3.03B | $3.37B | $3.26B | $3.13B | $3.22B | $3.72B | $3.57B | $3.63B | · | $3.74B | $3.61B | $3.50B | · | $3.33B | |
| Inventory | $3.93B | $3.93B | $4.00B | $4.11B | $4.26B | $4.10B | $3.85B | $4.08B | $3.94B | $3.82B | · | $3.67B | $3.64B | $3.66B | · | $3.38B | |
| Prepaid Expense | $2.11B | $2.11B | $1.44B | $1.49B | $1.69B | $1.65B | $1.71B | $1.63B | $1.76B | $1.93B | · | $1.78B | $1.73B | $1.76B | · | $1.70B | |
| Other Current Assets | $140M | $98M | $136M | $251M | $259M | $355M | $387M | $335M | $270M | $250M | · | $1.20B | $1.18B | $1.35B | · | $1.13B | |
| Current Assets | $10.06B | $10.92B | $9.79B | $9.95B | $9.77B | $9.62B | $9.52B | $11.31B | $11.79B | $12.92B | · | $10.93B | $9.78B | $9.63B | · | $10.49B | |
| PP&E (Net) | $2.44B | $2.53B | $2.61B | $2.63B | $2.64B | $2.64B | $2.67B | $2.68B | $2.66B | $2.71B | · | $2.93B | $2.98B | $3.01B | · | $3.04B | |
| PP&E (Gross) | $5.11B | $5.11B | $5.13B | $5.11B | $5.07B | $4.94B | $4.87B | $4.88B | $4.71B | $4.71B | · | $5.04B | $5.05B | $5.15B | · | $5.02B | |
| Accum. Depreciation | $2.67B | $2.58B | $2.52B | $2.48B | $2.42B | $2.30B | $2.20B | $2.21B | $2.05B | $2.00B | · | $2.11B | $2.06B | $2.14B | · | $1.98B | |
| Goodwill | $6.65B | $6.69B | $6.75B | $6.73B | $6.75B | $6.46B | $9.13B | $9.56B | $9.33B | $9.69B | $9.87B | $10.28B | $10.53B | $10.57B | $10.43B | $10.05B | |
| Intangibles | $13.68B | $14.48B | $15.10B | $15.72B | $16.32B | $16.66B | $17.07B | $17.98B | $18.42B | $19.13B | · | $21.28B | $22.08B | $22.70B | · | $23.01B | |
| Other Non-current Assets | $1.06B | $1.11B | $1.87B | $1.89B | $2.00B | $2.27B | $2.36B | $2.47B | $2.45B | $2.23B | · | $2.40B | $2.35B | $2.42B | · | $964M | |
| Total Assets | $35.04B | $36.83B | $37.19B | $37.92B | $38.41B | $38.47B | $41.50B | $44.75B | $45.33B | $47.34B | · | $48.74B | $48.70B | $49.29B | · | $48.66B | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | · | · | $100.0K | $23M | $205M | · | $500M | |
| Current Liabilities | $6.35B | $6.81B | $7.09B | $7.36B | $7.13B | $5.72B | $5.78B | $7.51B | $7.71B | $7.76B | · | $6.83B | $6.52B | $6.11B | · | $6.52B | |
| Capital Leases | $160M | $167M | $178M | $171M | $182M | $177M | $179M | $188M | $192M | $156M | · | $160M | $167M | $173M | · | $179M | |
| Deferred Tax | $803M | $871M | $892M | $1.03B | $1.08B | $1.08B | $1.11B | $1.28B | $1.57B | $1.67B | · | $2.32B | $2.41B | $2.46B | · | $2.49B | |
| Other Non-current Liabilities | $2.02B | $2.08B | $2.01B | $1.82B | $1.84B | $1.84B | $1.94B | $1.87B | $1.80B | $1.83B | · | $1.65B | $1.67B | $1.72B | · | $1.75B | |
| Total Liabilities | $20.78B | $22.18B | $22.48B | $22.70B | $22.84B | $22.82B | $22.87B | $24.96B | $25.81B | $27.33B | · | $27.88B | $27.85B | $28.36B | · | $29.48B | |
| Long-term Debt | $13.35B | $14.34B | $14.41B | $14.44B | $14.47B | $14.19B | $14.05B | $15.75B | $17.10B | $17.97B | · | $18.38B | $18.58B | $18.58B | · | $19.49B | |
| Total Debt | $13.35B | $14.34B | · | $14.44B | $14.47B | $14.19B | · | $15.75B | $17.10B | $17.97B | · | $18.38B | $18.60B | $18.78B | · | $19.99B | |
| Common Stock | $13M | $13M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | · | $12M | $12M | $12M | · | $12M | |
| Paid-in Capital | $18.56B | $18.66B | $18.80B | $18.89B | $19.00B | $18.96B | $18.92B | $18.89B | $18.85B | $18.84B | · | $18.76B | $18.72B | $18.68B | · | $18.62B | |
| Retained Earnings | $-331M | $-212M | $-388M | $-48M | $80M | $228M | $3.42B | $4.08B | $4.13B | $4.61B | · | $5.55B | $5.37B | $5.25B | · | $4.31B | |
| Treasury Stock | $1.16B | $1.01B | $1.01B | $924M | $856M | $680M | $504M | $504M | $504M | $504M | · | $252M | $252M | $252M | · | · | |
| AOCI | $-2.82B | $-2.80B | $-2.71B | $-2.71B | $-2.66B | $-2.87B | · | $-2.69B | $-2.98B | $-2.94B | · | $-3.21B | $-3.01B | $-2.76B | · | $-3.76B | |
| Stockholders' Equity | $14.26B | $14.66B | $14.71B | $15.22B | $15.57B | $15.65B | $18.64B | $19.79B | $19.52B | $20.01B | $20.47B | $20.87B | $20.84B | $20.93B | $21.07B | $19.18B | |
| Liabilities + Equity | $35.04B | $36.83B | $37.19B | $37.92B | $38.41B | $38.47B | $41.50B | $44.75B | $45.33B | $47.34B | · | $48.74B | $48.70B | $49.29B | · | $48.66B |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $672M | $676M | $767M | $688M | $678M | $665M | $746M | $670M | $786M | $691M | $644M | $679M | $687M | $730M | $870M | $700M | |
| Stock-based Comp | $39M | $48M | $49M | $36M | $37M | $55M | $32M | $32M | $35M | $47M | $56M | $43M | $39M | $43M | $30M | $29M | |
| Deferred Tax | $-124M | $-70M | $-248M | $-137M | $-48M | $-44M | $-249M | $-312M | $-154M | $-52M | $-207M | $-85M | $-68M | $-27M | $154M | $-22M | |
| Amort. of Intangibles | $572M | $585M | $602M | $593M | $583M | $571M | $579M | $575M | $597M | $601M | $539M | $584M | $591M | $603M | $606M | $616M | |
| Restructuring | $27M | $78M | · | · | · | · | · | · | · | · | · | $15M | $74M | $10M | · | $15M | |
| Operating Cash Flow | $382M | $388M | $816M | $745M | $220M | $536M | $483M | $826M | $379M | $615M | $568M | $845M | $525M | $971M | $189M | $869M | |
| CapEx | $53M | $40M | $196M | $87M | $53M | $43M | $140M | $77M | $59M | $50M | $166M | $96M | $68M | $48M | $154M | $104M | |
| Investing Cash Flow | $-52M | $277M | $-211M | $-99M | $-52M | $-65M | $-169M | $1.75B | $376M | $-154M | $27M | $-65M | $-87M | $-750M | $1.74B | $-115M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | $300.0K | $0 | $0 | $0 | $100.0K | $1.08B | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $-750M | · | · | |
| Stock Issued | $700.0K | $500.0K | $600.0K | $700.0K | $700.0K | $600.0K | $600.0K | $600.0K | $700.0K | $600.0K | $600.0K | $800.0K | $800.0K | $900.0K | $800.0K | $2M | |
| Stock Repurchased | $150M | $0 | $82M | $68M | $175M | $175M | $0 | $0 | $0 | $250M | $0 | $0 | $0 | $250M | $0 | $0 | |
| Net Stock Activity | · | $500.0K | · | $-68M | $-175M | $-175M | · | · | · | $-249M | · | · | · | $-249M | · | · | |
| Financing Cash Flow | $-1.24B | $-204M | $-236M | $-228M | $-362M | $-467M | $-1.42B | $-1.64B | $-848M | $-426M | $-926M | $-98M | $-304M | $-975M | $-1.33B | $-759M | |
| Net Change in Cash | $-916M | $458M | $344M | $436M | $-188M | $20M | $-1.14B | $962M | $-97M | $22M | $-318M | $680M | $121M | $-752M | $612M | $-19M | |
| Free Cash Flow | · | $348M | · | · | · | $493M | · | · | · | $565M | · | · | · | $923M | · | · | |
| Levered FCF | · | $434M | · | · | · | $379M | · | · | · | $488M | · | · | · | $821M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.8% | 32.9% | · | 36.5% | 37.2% | 35.7% | · | 38.9% | 38.1% | 41.0% | · | 42.9% | 41.0% | 41.4% | · | 42.9% | |
| Operating Margin | 0.17% | -2.3% | · | 4.8% | 6.5% | -88.6% | · | 6.0% | -6.3% | 5.6% | · | 11.5% | 9.4% | 10.7% | · | 13.7% | |
| Pretax Margin | -1.7% | -7.0% | · | -0.21% | -6.1% | -95.2% | · | 2.4% | -10.3% | 5.6% | · | 10.2% | 8.5% | 8.6% | · | 10.5% | |
| EBITDA Margin | 0.17% | 17.0% | · | 4.8% | 6.5% | -68.1% | · | 6.0% | -6.3% | 24.4% | · | 11.5% | 9.4% | 30.3% | · | 13.7% | |
| ROIC | 0.04% | 0.20% | · | 9.8% | 0.02% | -9.5% | · | 0.67% | -0.55% | 0.30% | · | 0.95% | 0.74% | 0.70% | · | 1.2% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.6 | · | 1.4 | 1.4 | 1.7 | · | 1.5 | 1.5 | 1.7 | · | 1.6 | 1.5 | 1.6 | · | 1.6 | |
| Quick Ratio | 0.6 | 0.7 | · | 0.6 | 0.5 | 0.7 | · | 0.7 | 0.6 | 0.6 | · | 0.7 | 0.6 | 0.7 | · | 0.6 | |
| Debt / Equity | 0.9 | 1.0 | · | 0.9 | 0.9 | 0.9 | · | 0.8 | 0.9 | 0.9 | · | 0.9 | 0.9 | 0.9 | · | 1.0 | |
| LT Debt / Equity | 0.8 | 0.8 | · | 0.8 | 0.8 | 0.9 | · | 0.7 | 0.8 | 0.8 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Interest Coverage | 0.1 | -0.7 | · | 1.5 | 2.0 | -25.0 | · | 1.6 | -1.6 | 1.5 | · | 3.2 | 2.6 | 2.7 | · | 3.7 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.6 | 0.6 | · | 0.6 | 0.5 | 0.5 | · | 0.6 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | 0.6 | |
| Receivables Turnover | 1.2 | 1.1 | · | 1.1 | 1.0 | 1.0 | · | 1.0 | 1.1 | 1.0 | · | 1.1 | 1.1 | 1.0 | · | 1.1 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $3.23 | $2.99 | · | $3.23 | $3.05 | $2.73 | · | $3.12 | $3.19 | $3.03 | · | · | · | $3.09 | · | $3.35 | |
| Cash Flow / Share | · | $0.33 | · | · | · | $0.45 | · | · | · | $0.51 | · | · | · | $0.81 | · | · | |
| Dividend / Share | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0.12 | |
| Dividend Paid / Share | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | |
| EPS (TTM) | $-0.40 | $-0.30 | · | $-3.09 | $-2.90 | $-3.17 | · | $-0.73 | $-0.54 | $-0.05 | · | $1.51 | $1.53 | $1.57 | · | $0.66 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14.74B | $14.56B | · | $14.12B | $14.12B | $14.33B | · | $15.05B | $15.24B | $15.36B | · | $15.47B | $15.60B | $15.80B | · | $16.73B | |
| Net Income TTM | $-670M | $-670M | · | $-670M | $-670M | $-670M | · | $-670M | $-670M | $-670M | · | $-670M | $-670M | $-670M | · | $-670M | |
| P/E | -39.7 | -45.0 | · | -3.2 | -3.1 | -2.7 | · | -15.9 | -19.7 | -238.8 | · | 6.5 | 6.5 | 6.1 | · | 12.9 | |
| Earnings Yield | -2.5% | -2.2% | · | -31.2% | -32.5% | -36.4% | · | -6.3% | -5.1% | -0.42% | · | 15.3% | 15.3% | 16.3% | · | 7.8% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $14.30B | $14.74B | $15.43B | $16.26B | $17.89B |
| Marża Brutto % | 35.1% | · | · | · | · |
| Marża Operacyjna % | -18.6% | · | · | · | · |
| Zysk netto | $-3.51B | $-634M | $55M | $2.08B | $-1.27B |
| Rozwodniony EPS | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 1.0 | · | · | · | · |
| Wskaźnik bieżący | 1.4 | · | · | · | · |
| Wskaźnik Szybkości | 0.6 | · | · | · | · |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $1.94B | · | · | · | · |
Właściciele instytucjonalni (13F) 1 118 emitentów · $17.2B łącznie · Na dzień 30 września 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Posiadacze
1 118
Wartość posiadanych akcji
$17.2B
Nowe pozycje
109
Zamknięte pozycje
87
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 109 (-47 vs poprzedni kw.) | 87 (-2 vs poprzedni kw.) | 373 (+25 vs poprzedni kw.) | 325 (+14 vs poprzedni kw.) | +90.9M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $1 720 339 307 | 138 179 864 | 10,03% | Akcje |
| FMR LLC | $1 534 994 190 | 96 662 102 | 8,95% | Akcje |
| BlackRock, Inc. | $1 365 989 163 | 86 019 468 | 7,96% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $1 207 625 391 | 76 046 939 | 7,04% | Akcje |
| Davis Selected Advisers | $1 194 789 797 | 75 232 254 | 6,96% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $861 999 430 | 54 282 080 | 5,02% | Akcje |
| STATE STREET CORP | $842 743 041 | 53 069 461 | 4,91% | Akcje |
| Rubric Capital Management LP | $542 599 639 | 34 168 743 | 3,16% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $520 097 655 | 32 807 906 | 3,03% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $475 964 429 | 29 970 094 | 2,77% | Akcje |
| Invesco Ltd. | $329 847 848 | 20 771 275 | 1,92% | Akcje |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $320 873 980 | 20 206 170 | 1,87% | Akcje |
| AMERIPRISE FINANCIAL INC | $298 795 923 | 18 815 747 | 1,74% | Akcje |
| MORGAN STANLEY | $240 246 939 | 15 128 899 | 1,40% | Akcje |
| Bank of New York Mellon Corp | $226 894 280 | 14 288 053 | 1,32% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $215 449 390 | 13 567 342 | 1,26% | Akcje |
| GOLDMAN SACHS GROUP INC | $215 410 160 | 13 564 872 | 1,26% | Akcje |
| NORTHERN TRUST CORP | $159 414 412 | 10 038 691 | 0,93% | Akcje |
| GLENVIEW CAPITAL MANAGEMENT, LLC | $156 853 255 | 9 877 409 | 0,91% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $132 934 942 | 8 371 218 | 0,77% | Akcje |
| Callodine Capital Management, LP | $127 051 783 | 8 000 742 | 0,74% | Akcje |
| DEUTSCHE BANK AG\ | $125 313 384 | 7 891 271 | 0,73% | Akcje |
| JPMORGAN CHASE & CO | $119 690 536 | 7 322 267 | 0,70% | Akcje |
| BANK OF AMERICA CORP /DE/ | $116 824 517 | 7 356 708 | 0,68% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $103 910 383 | 6 543 475 | 0,61% | Akcje |
| Qube Research & Technologies Ltd | $98 141 941 | 6 180 223 | 0,57% | Akcje |
| UBS Group AG | $96 745 659 | 6 092 296 | 0,56% | Akcje |
| Nuveen, LLC | $95 398 563 | 6 007 467 | 0,56% | Akcje |
| FRANKLIN RESOURCES INC | $89 856 011 | 5 658 439 | 0,52% | Akcje |
| JANE STREET GROUP, LLC | $88 440 659 | 5 569 311 | 0,52% | Akcje |
| Nantahala Capital Management, LLC | $79 400 000 | 5 000 000 | 0,46% | Opcja kupna |
| Assenagon Asset Management S.A. | $79 225 415 | 4 989 006 | 0,46% | Akcje |
| AQR CAPITAL MANAGEMENT LLC | $74 556 065 | 4 694 966 | 0,43% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $73 760 258 | 4 644 851 | 0,43% | Akcje |
| Gotham Asset Management, LLC | $69 469 966 | 4 374 683 | 0,40% | Akcje |
| CITIGROUP INC | $69 243 850 | 4 360 444 | 0,40% | Akcje |
| Brandywine Global Investment Management, LLC | $67 528 501 | 5 423 976 | 0,39% | Akcje |
| Legal & General Group Plc | $64 625 994 | 4 069 647 | 0,38% | Akcje |
| NORGES BANK | $60 705 175 | 3 822 744 | 0,35% | Akcje |
| LAKEWOOD CAPITAL MANAGEMENT, LP | $59 326 092 | 3 735 900 | 0,35% | Akcje |
| Man Group plc | $55 946 065 | 3 523 052 | 0,33% | Akcje |
| Russell Investments Group, Ltd. | $54 379 234 | 3 423 675 | 0,32% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $53 562 152 | 3 964 630 | 0,31% | Akcje |
| Amundi | $51 920 530 | 3 269 550 | 0,30% | Akcje |
| SEI INVESTMENTS CO | $50 267 814 | 3 165 469 | 0,29% | Akcje |
| ROYAL BANK OF CANADA | $49 792 000 | 3 135 460 | 0,29% | Akcje |
| RHUMBLINE ADVISERS | $45 614 656 | 2 872 464 | 0,27% | Akcje |
| DME Capital Management, LP | $44 042 703 | 2 773 470 | 0,26% | Akcje |
| Vanguard Global Advisers, LLC | $42 862 486 | 2 699 149 | 0,25% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $42 610 407 | 2 683 275 | 0,25% | Akcje |
Insiderzy spółki 32 insiderów · 14 dyrektorzy generalni · 20 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Scott Andrew Smith | Chief Executive Officer | 6 marca 2026 A | 1 329 326 | 0 | 0 | $0 |
| Michael Goettler | Chief Executive Officer | 4 marca 2023 M | 321 653 | 0 | 0 | $0 |
| Campbell Paul | Interim Chief Financial Officer, Chief Accounting Officer and Corporate Controller | 25 czerwca 2026 S | 316 212 | 0 | 2 | $-1 093 257 |
| Theodora Mistras | Chief Financial Officer | 6 marca 2026 A | 70 645 | 0 | 0 | $0 |
| Sanjeev Narula | Chief Financial Officer | 4 marca 2023 M | 73 877 | 0 | 0 | $0 |
| Anthony Mauro | President, Developed Markets | 13 marca 2024 S | 243 044 | 0 | 0 | $0 |
| Xiangyang (Sean) Ni | President, Greater China | 4 marca 2024 A | 90 804 | 0 | 0 | $0 |
| Andrew Cuneo | President, JANZ (Japan, Australia and New Zealand) and Emerging Markets | 4 marca 2024 A | 60 055 | 0 | 0 | $0 |
| Menassie Taddese | President, Emerging Markets | 27 maja 2022 S | 0 | 0 | 0 | $0 |
| Andrew Enrietti | Chief Administrative and Transformation Officer | 15 sierpnia 2026 M | 234 444 | 0 | 0 | $0 |
| Corinne Le Goff | Chief Commercial Officer | 15 kwietnia 2026 M | 107 135 | 0 | 0 | $0 |
| Matthew Joseph Maletta | Chief Legal Officer | 6 marca 2026 A | · | 0 | 0 | $0 |
| Brian Roman | Chief Legal Officer | 6 marca 2025 A | 193 916 | 0 | 0 | $0 |
| Robert J Coury | Executive Chairman | 4 marca 2023 M | 1 174 515 | 0 | 0 | $0 |
| Leo Frans Groothuis | Dyrektor | 30 września 2026 A | 63 437 | 0 | 0 | $0 |
| David S Simmons | Dyrektor | 30 września 2026 A | 23 344 | 2 | 0 | $5 202 |
| Richard A Mark | Dyrektor | 6 marca 2026 A | 116 145 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | Dyrektor | 6 marca 2026 A | 46 526 | 0 | 0 | $0 |
| Michael Severino | Dyrektor | 6 marca 2026 A | 26 031 | 0 | 0 | $0 |
| Dillon Joellen Lyons | Dyrektor | 6 marca 2026 A | 102 526 | 0 | 0 | $0 |
| Mark W Parrish | Dyrektor | 6 marca 2026 A | 165 230 | 0 | 0 | $0 |
| Elisha W Finney | Dyrektor | 6 marca 2026 A | 62 667 | 0 | 0 | $0 |
| Frank A Damelio | Dyrektor | 6 marca 2026 A | 26 031 | 0 | 0 | $0 |
| Don W Cornwell | Dyrektor | 6 marca 2026 A | 112 044 | 0 | 0 | $0 |
| Melina E Higgins | Dyrektor | 6 marca 2026 A | 146 048 | 0 | 0 | $0 |
| James M Kilts | Dyrektor | 6 marca 2026 A | 161 257 | 0 | 0 | $0 |
| Rajiv Malik | Dyrektor | 6 marca 2025 A | 1 068 262 | 0 | 0 | $0 |
| Harry Korman | Dyrektor | 6 marca 2025 A | 113 937 | 0 | 0 | $0 |
| Mohr Pauline Van Der Meer | Dyrektor | 4 marca 2023 M | 40 245 | 0 | 0 | $0 |
| Ian C Read | Dyrektor | 21 marca 2022 M | 14 497 | 0 | 0 | $0 |
| Neil F Dimick | Dyrektor | 21 marca 2022 M | 75 200 | 0 | 0 | $0 |
| Pfizer Inc. | Posiadacz 10% | 16 listopada 2020 J | 0 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 123 fundusze ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| DUSA · Davis Fundamental ETF Trust | 5,37% | 3 886 641 NS | 31 lipca 2026 | N-PORT |
| ADPV · Series Portfolios Trust | 4,75% | 482 110 NS | 31 lipca 2026 | N-PORT |
| DWLD · Davis Fundamental ETF Trust | 4,37% | 1 522 109 NS | 31 lipca 2026 | N-PORT |
| IHE · iShares Trust | 4,36% | 4 310 454 SH | 11 września 2026 | Dziennie |
| PJP · Invesco Exchange-Traded Fund Trust | 3,40% | 1 069 356 SH | 1 października 2026 | Dziennie |
| CVSM · Elevation Series Trust | 2,66% | 143 081 NS | 31 lipca 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 2,51% | 21 853 NS | 31 lipca 2026 | N-PORT |
| SPDV · ETF Series Solutions | 2,41% | 180 356 NS | 31 lipca 2026 | N-PORT |
| LYLD · Cambria ETF Trust | 2,03% | 8 379 NS | 31 lipca 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,76% | 865 399 SH | 1 października 2026 | Dziennie |
| PTH · Invesco Exchange-Traded Fund Trust | 1,75% | 363 657 SH | 1 października 2026 | Dziennie |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,50% | 896 631 NS | 31 lipca 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,33% | 81 239 SH | 1 października 2026 | Dziennie |
| RPV · Invesco Exchange-Traded Fund Trust | 1,30% | 1 201 310 SH | 1 października 2026 | Dziennie |
| PILL · Direxion Shares ETF Trust | 1,27% | 14 896 NS | 31 lipca 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 1,07% | 786 966 NS | 31 lipca 2026 | N-PORT |
| SYLD · Cambria ETF Trust | 1,04% | 587 982 NS | 31 lipca 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1,04% | 98 896 SH | 1 października 2026 | Dziennie |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,82% | 60 381 SH | 1 października 2026 | Dziennie |
| IQSM · New York Life Investments ETF Trust | 0,78% | 146 604 NS | 31 lipca 2026 | N-PORT |
| CVY · Invesco Exchange-Traded Fund Trust | 0,75% | 49 232 SH | 1 października 2026 | Dziennie |
| MEDI · Harbor ETF Trust | 0,57% | 13 424 NS | 31 lipca 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,54% | 5 774 795 NS | 31 lipca 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,51% | 187 532 NS | 31 lipca 2026 | N-PORT |
| FNK · First Trust Exchange-Traded AlphaDE… | 0,47% | 61 211 NS | 31 lipca 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,43% | 113 494 NS | 31 lipca 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,43% | 493 425 NS | 31 lipca 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0,39% | 16 955 526 SH | 19 sierpnia 2026 | Dziennie |
| FBCV · FIDELITY COVINGTON TRUST | 0,39% | 39 217 NS | 31 lipca 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,39% | 329 029 NS | 31 lipca 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,36% | 10 810 000 | 1 października 2026 | Dziennie |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,35% | 91 816 NS | 31 lipca 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,35% | 2 881 753 NS | 31 lipca 2026 | N-PORT |
| IYH · iShares Trust | 0,31% | 680 750 SH | 11 września 2026 | Dziennie |
| FHLC · FIDELITY COVINGTON TRUST | 0,30% | 554 689 NS | 31 lipca 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,28% | 150 960 SH | 19 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,27% | 3 499 976 SH | 19 sierpnia 2026 | Dziennie |
| ESML · iShares Trust | 0,27% | 455 933 SH | 11 września 2026 | Dziennie |
| SMMD · iShares Trust | 0,26% | 621 073 SH | 11 września 2026 | Dziennie |
| REVS · Columbia ETF Trust I | 0,26% | 49 916 NS | 31 lipca 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,26% | 115 598 SH | 19 sierpnia 2026 | Dziennie |
| IMCV · iShares Trust | 0,26% | 182 951 SH | 11 września 2026 | Dziennie |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,26% | 122 266 NS | 31 lipca 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,25% | 194 588 NS | 31 lipca 2026 | N-PORT |
| IXJ · iShares Trust | 0,24% | 611 025 SH | 11 września 2026 | Dziennie |
| CURE · Direxion Shares ETF Trust | 0,23% | 22 916 NS | 31 lipca 2026 | N-PORT |
| RSP · Invesco Exchange-Traded Fund Trust | 0,22% | 11 867 062 SH | 1 października 2026 | Dziennie |
| VB · VANGUARD INDEX FUNDS | 0,22% | 26 707 011 SH | 19 sierpnia 2026 | Dziennie |
| IWS · iShares Trust | 0,19% | 1 735 168 SH | 11 września 2026 | Dziennie |
| WSML · iShares Trust | 0,18% | 71 909 SH | 11 września 2026 | Dziennie |
| RECS · Columbia ETF Trust I | 0,17% | 566 625 NS | 31 lipca 2026 | N-PORT |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,17% | 7 807 000 | 1 października 2026 | Dziennie |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,16% | 228 156 NS | 31 lipca 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,15% | 187 618 SH | 19 sierpnia 2026 | Dziennie |
| LGDX · Tidal Trust III | 0,15% | 11 980 NS | 31 lipca 2026 | N-PORT |
| SPMO · Invesco Exchange-Traded Fund Trust … | 0,15% | 1 925 017 SH | 1 października 2026 | Dziennie |
| FAB · First Trust Exchange-Traded AlphaDE… | 0,14% | 13 535 NS | 31 lipca 2026 | N-PORT |
| IWR · iShares Trust | 0,14% | 4 755 593 SH | 11 września 2026 | Dziennie |
| IMCB · iShares Trust | 0,13% | 131 500 SH | 10 września 2026 | Dziennie |
| DFVX · Dimensional ETF Trust | 0,12% | 36 388 NS | 31 lipca 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,11% | 622 740 SH | 1 października 2026 | Dziennie |
| FBCG · FIDELITY COVINGTON TRUST | 0,11% | 438 116 NS | 31 lipca 2026 | N-PORT |
| XOEF · iShares Trust | 0,11% | 1 446 SH | 11 września 2026 | Dziennie |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,10% | 46 067 SH | 1 października 2026 | Dziennie |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,10% | 55 744 SH | 1 października 2026 | Dziennie |
| DIVB · iShares Trust | 0,10% | 124 028 SH | 11 września 2026 | Dziennie |
| DFUV · Dimensional ETF Trust | 0,09% | 825 072 NS | 31 lipca 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,08% | 445 662 SH | 1 października 2026 | Dziennie |
| VYM · VANGUARD WHITEHALL FUNDS | 0,08% | 4 647 551 SH | 19 sierpnia 2026 | Dziennie |
| DFLV · Dimensional ETF Trust | 0,07% | 272 031 NS | 31 lipca 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,07% | 21 814 NS | 31 lipca 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,06% | 1 747 680 NS | 31 lipca 2026 | N-PORT |
| IVE · iShares Trust | 0,06% | 1 934 171 SH | 11 września 2026 | Dziennie |
| IUSV · iShares Trust | 0,06% | 1 017 393 SH | 11 września 2026 | Dziennie |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,06% | 267 075 SH | 19 sierpnia 2026 | Dziennie |
| DCOR · Dimensional ETF Trust | 0,06% | 110 597 NS | 31 lipca 2026 | N-PORT |
| ILCV · iShares Trust | 0,05% | 44 089 SH | 11 września 2026 | Dziennie |
| IWD · iShares Trust | 0,05% | 2 579 107 SH | 11 września 2026 | Dziennie |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,05% | 701 858 SH | 19 sierpnia 2026 | Dziennie |
| DFAS · Dimensional ETF Trust | 0,04% | 358 281 NS | 31 lipca 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,04% | 52 351 NS | 31 lipca 2026 | N-PORT |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,04% | 35 636 SH | 1 października 2026 | Dziennie |
| DFAU · Dimensional ETF Trust | 0,04% | 267 915 NS | 31 lipca 2026 | N-PORT |
| TOPC · iShares Trust | 0,04% | 720 SH | 9 września 2026 | Dziennie |
| XRMI · Global X Funds | 0,04% | 1 009 NS | 31 lipca 2026 | N-PORT |
| XYLG · Global X Funds | 0,03% | 1 200 NS | 31 lipca 2026 | N-PORT |
| XVV · iShares Trust | 0,03% | 13 227 SH | 11 września 2026 | Dziennie |
| XYLD · Global X Funds | 0,03% | 58 008 NS | 31 lipca 2026 | N-PORT |
| PTLC · Pacer Funds Trust | 0,03% | 58 253 NS | 31 lipca 2026 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0,03% | 6 830 SH | 1 października 2026 | Dziennie |
| XTR · Global X Funds | 0,03% | 85 NS | 31 lipca 2026 | N-PORT |
| TILT · FlexShares Trust | 0,03% | 37 920 NS | 31 lipca 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,03% | 362 786 NS | 31 lipca 2026 | N-PORT |
| XCLR · Global X Funds | 0,03% | 62 NS | 31 lipca 2026 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0,03% | 30 255 873 SH | 19 sierpnia 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,03% | 36 993 850 SH | 19 sierpnia 2026 | Dziennie |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,03% | 192 700 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,03% | 97 596 SH | 19 sierpnia 2026 | Dziennie |
| ESGV · VANGUARD WORLD FUND | 0,03% | 262 709 SH | 19 sierpnia 2026 | Dziennie |
| TOV · EA Series Trust | 0,03% | 4 573 NS | 31 lipca 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,03% | 4 394 NS | 31 lipca 2026 | N-PORT |
| IVV · iShares Trust | 0,03% | 14 678 463 SH | 11 września 2026 | Dziennie |
| QDPL · Pacer Funds Trust | 0,03% | 28 053 NS | 31 lipca 2026 | N-PORT |
| ILCB · iShares Trust | 0,03% | 21 777 SH | 11 września 2026 | Dziennie |
| IWB · iShares Trust | 0,03% | 814 020 SH | 11 września 2026 | Dziennie |
| IYY · iShares Trust | 0,03% | 49 059 SH | 11 września 2026 | Dziennie |
| LRGF · iShares Trust | 0,03% | 59 492 SH | 11 września 2026 | Dziennie |
| ITOT · iShares Trust | 0,03% | 1 524 327 SH | 11 września 2026 | Dziennie |
| IWV · iShares Trust | 0,03% | 315 944 SH | 11 września 2026 | Dziennie |
| HCMT · Direxion Shares ETF Trust | 0,03% | 8 100 NS | 31 lipca 2026 | N-PORT |
| PHDG · Invesco Actively Managed Exchange-T… | 0,02% | 863 SH | 1 października 2026 | Dziennie |
| SPXL · Direxion Shares ETF Trust | 0,02% | 91 048 NS | 31 lipca 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,02% | 993 914 SH | 19 sierpnia 2026 | Dziennie |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,02% | 41 980 SH | 1 października 2026 | Dziennie |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30 lipca 2026 | Dziennie |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 lipca 2026 | Dziennie |
| BNDX · VANGUARD CHARLOTTE FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCEB · VANGUARD WORLD FUND | · | · | 30 lipca 2026 | Dziennie |
VTRS Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
ocena · 17 analityków
KUP
Średni cel
$20.00
+13,6%
4 23,5%
Mocne kupno
7 41,2%
Kup
5 29,4%
Trzymaj
1 5,9%
Sprzedaj
0 0,0%
Mocna sprzedaż
12-miesięczny cel cenowy
10 analityków · 2026-09-30Średnia cel $19.40 +10,2%
Teraz
Aktualna cena $17.60
Niski$13.00
Średnia$19.40
Wysoki$25.00
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| VTRS | · | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| MRK | · | 14.5 | 1.3% | 28.1% | 36.9% | · |
| PFE | · | 18.3 | -1.7% | 12.4% | 8.9% | · |
| BMY | · | 15.6 | -0.22% | 14.6% | 40.5% | · |
| RPRX | · | 21.7 | 5.1% | 32.4% | 8.0% | · |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | · |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | · |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Co Inwestorzy Powinni Wiedzieć o Wyjściu z Akcji Sprzętu Medycznego o Wartości 24 Milionów USD, Które Spadły o 9% w Minionym Roku
Nasdaq · 6 miesięcy, 1 tydzień temu
Viatris przedstawia długoterminowe cele finansowe
Nasdaq · 6 miesięcy, 2 tygodnie temu
Co mówią analitycy o akcjach Viatris Inc (VTRS)?
Yahoo Finance · 6 miesięcy, 2 tygodnie temu
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Źródło: SEC 10-Q złożone Sie 6, 2026